Forcefield Ventures

Forcefield Therapeutics is a specialized biotechnology company developing gene therapies for unmet medical needs from an undisclosed headquarters location. Operating as a portfolio company, the business is entirely funded and supported by life sciences venture capital investor Syncona. The organization focuses on creating targeted treatments for conditions such as retinal diseases, helping patients requiring advanced genetic interventions. The executive leadership team includes Chairman Hollowood, who previously chaired Nightstar before its 877 million dollar sale to Biogen, and Gyroscope, which was acquired by Novartis for up to one and a half billion dollars in 2022. Additionally, Board Director and Syncona Partner Elisa Petris has been heavily involved in establishing the operational and strategic setup of the growing firm. The exact founding year, overall business scale, and the names of the original founders remain publicly undisclosed at this time.